{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T04:19:13Z","timestamp":1765772353665},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007801","name":"Fundaci\u00f3n S\u00e9neca","doi-asserted-by":"publisher","award":["19245\/PI\/14"],"award-info":[{"award-number":["19245\/PI\/14"]}],"id":[{"id":"10.13039\/100007801","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto Murciano de Investigaci\u00f3n Biosanitaria","award":["IMIB16\/AP\/01\/06"],"award-info":[{"award-number":["IMIB16\/AP\/01\/06"]}]}],"content-domain":{"domain":["clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.mayocp.2018.01.028","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T18:38:14Z","timestamp":1525286294000},"page":"1065-1073","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the \u201cReal-World\u201d vs Clinical Trials"],"prefix":"10.1016","volume":"93","author":[{"given":"Jos\u00e9 Miguel","family":"Rivera-Caravaca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Asunci\u00f3n","family":"Esteve-Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Vald\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mayocp.2018.01.028_bib1","first-page":"1087","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis\u2013Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.mayocp.2018.01.028_bib2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"19","key":"10.1016\/j.mayocp.2018.01.028_bib3","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.288.19.2441","article-title":"Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis","volume":"288","author":"van Walraven","year":"2002","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.mayocp.2018.01.028_bib4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/europace\/eut333","article-title":"Atrial fibrillation patients do not benefit from acetylsalicylic acid","volume":"16","author":"Sj\u00e4lander","year":"2014","journal-title":"Europace"},{"issue":"9586","key":"10.1016\/j.mayocp.2018.01.028_bib5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.mayocp.2018.01.028_bib6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.mayocp.2016.03.007","article-title":"Impact on outcomes of changing treatment guideline recommendations for stroke prevention in atrial fibrillation: a nationwide cohort study","volume":"91","author":"Chao","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.mayocp.2018.01.028_bib7","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/europace\/euv269","article-title":"Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry","volume":"17","author":"Lip","year":"2015","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.mayocp.2018.01.028_bib8","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ijcard.2014.07.098","article-title":"Adherence to guidelines and mortality in atrial fibrillation","volume":"176","author":"Diez-Manglano","year":"2014","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.mayocp.2018.01.028_bib9","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.mayocp.2018.01.028_bib10","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.12688\/f1000research.10176.1","article-title":"Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention","volume":"5","author":"Shahid","year":"2016","journal-title":"F1000Res"},{"issue":"4","key":"10.1016\/j.mayocp.2018.01.028_bib11","first-page":"587","article-title":"\u201cUnreal world\u201d or \u201creal world\u201d data in oral anticoagulant treatment of atrial fibrillation","volume":"116","author":"Freedman","year":"2016","journal-title":"Thromb Haemost"},{"issue":"392","key":"10.1016\/j.mayocp.2018.01.028_bib12","first-page":"153","article-title":"Use of warfarin in non-rheumatic atrial fibrillation: a commentary from general practice","volume":"45","author":"Sweeney","year":"1995","journal-title":"Br J Gen Pract"},{"issue":"5","key":"10.1016\/j.mayocp.2018.01.028_bib13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/1755-5922.12087","article-title":"External validity of the ARISTOTLE trial in real-life atrial fibrillation patients","volume":"32","author":"Hagg","year":"2014","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.mayocp.2018.01.028_bib14","doi-asserted-by":"crossref","first-page":"e3863","DOI":"10.1136\/bmj.e3863","article-title":"Problems of stopping trials early","volume":"344","author":"Guyatt","year":"2012","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.mayocp.2018.01.028_bib15","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.2010.310","article-title":"Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis","volume":"303","author":"Bassler","year":"2010","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mayocp.2018.01.028_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.mayocp.2018.01.028_bib17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"9609","key":"10.1016\/j.mayocp.2018.01.028_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(08)60168-3","article-title":"Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial","volume":"371","author":"Bousser","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mayocp.2018.01.028_bib19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"25","key":"10.1016\/j.mayocp.2018.01.028_bib20","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.mayocp.2018.01.028_bib21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"12","key":"10.1016\/j.mayocp.2018.01.028_bib22","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2018.01.028_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2018.01.028_bib24","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.mayocp.2018.01.028_bib25","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2018.01.028_bib26","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.amjmed.2014.05.003","article-title":"Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey","volume":"127","author":"Marcucci","year":"2014","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2018.01.028_bib27","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1160\/TH16-12-0961","article-title":"Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients","volume":"117","author":"Rivera-Caravaca","year":"2017","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.mayocp.2018.01.028_bib28","doi-asserted-by":"crossref","first-page":"e014579","DOI":"10.1136\/bmjopen-2016-014579","article-title":"Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry","volume":"7","author":"Camm","year":"2017","journal-title":"BMJ Open"},{"issue":"38","key":"10.1016\/j.mayocp.2018.01.028_bib29","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/eurheartj\/ehw233","article-title":"Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF","volume":"37","author":"Bassand","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.mayocp.2018.01.028_bib30","first-page":"975","article-title":"Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin: a propensity score matched analysis","volume":"116","author":"Lip","year":"2016","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.mayocp.2018.01.028_bib31","doi-asserted-by":"crossref","first-page":"e003725","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.mayocp.2018.01.028_bib32","first-page":"1093","article-title":"Dabigatran in \u2018real-world\u2019 clinical practice for stroke prevention in patients with non-valvular atrial fibrillation","volume":"114","author":"Potpara","year":"2015","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.mayocp.2018.01.028_bib33","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1160\/TH13-12-1032","article-title":"Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation","volume":"111","author":"Hylek","year":"2014","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.mayocp.2018.01.028_bib34","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1080\/03007995.2016.1254604","article-title":"How to REVISIT the increasing \u201creal world\u201d evidence for stroke prevention in non-valvular atrial fibrillation?","volume":"32","author":"Lip","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.mayocp.2018.01.028_bib35","author":"Fiminska"},{"issue":"2","key":"10.1016\/j.mayocp.2018.01.028_bib36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/2229-516X.157148","article-title":"Real world data: additional source for making clinical decisions","volume":"5","author":"Mahajan","year":"2015","journal-title":"Int J Appl Basic Med Res"},{"issue":"9","key":"10.1016\/j.mayocp.2018.01.028_bib37","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1182\/blood-2007-11-123711","article-title":"Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based","volume":"111","author":"Levi","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2018.01.028_bib38","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ajh\/hpx135","article-title":"Hypertension and atrial fibrillation: balancing stroke and bleeding risks","volume":"30","author":"Esteve-Pastor","year":"2017","journal-title":"Am J Hypertens"},{"issue":"12","key":"10.1016\/j.mayocp.2018.01.028_bib39","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jacep.2017.04.024","article-title":"Patients with atrial fibrillation who are not on anticoagulant treatment due to increased bleeding risk are common and have a high risk of stroke","volume":"3","author":"Redfors","year":"2017","journal-title":"JACC Clin Electrophysiol"},{"issue":"9","key":"10.1016\/j.mayocp.2018.01.028_bib40","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/14740338.2017.1351542","article-title":"Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation","volume":"16","author":"Rivera-Caravaca","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.mayocp.2018.01.028_bib41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/europace\/euv317","article-title":"Patients' attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association","volume":"18","author":"Amara","year":"2016","journal-title":"Europace"},{"issue":"7","key":"10.1016\/j.mayocp.2018.01.028_bib42","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619618301174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619618301174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T02:25:14Z","timestamp":1534904714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619618301174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0025619618301174"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2018.01.028","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the \u201cReal-World\u201d vs Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2018.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}